Marina Biotech, Inc. (OTCMKTS:MRNA) reported that it has obtained a “notice of allowance” from the European Patent Office. It is related with the intent to grant the claims in its application which covers SMARTICLES® amphoteric liposomes formulated with an extensive range of unique sterol amphiphiles. Also, it obtained a “notice of allowance” of Canada Patent which covers methods for formulating a broad range of amphoteric liposomes. It covers SMARTICLES formulation which is currently in Phase 1 and Phase 2 clinical studies.
Marina Biotech stated that these patents cover both improved properties of its SMARTICLES formulation, like a modifiable charge and fusogenicity. The continued issuance and allowance of SMARTICLES-related patents extends the worldwide portfolio of nucleic acid delivery technology. Michael French, the CEO and President of Marina Biotech, said that the Canadian and European patents will be a major inclusion in the SMARTICLES global portfolio as the company continues to gather data that shows the clinical versatility of SMARTICLES.
Most recently, SMARTICLES have shown cargo delivery outside the liver, as seen in part by Mirna Therapeutics’ report of SMARTICLES-mediated delivery. Expanding the reach of SMARTICLES shields one of Marina Biotech’s key delivery technologies and continues to facilitate company’s strategy to have most comprehensive and broadest nucleic acid drug discovery feature in the sector.
The company received a milestone payment from Marina Biotech, Inc. (OTCMKTS:MRNA), which considerably helped it to improve its cash position enabling it to move forward with the clinical plans. The focus is on preclinical and clinical plans and getting addition funds through near term licensing and collaboration deals.
In last trading session, the stock price of MRNA surged more than 10% to close the trading session at $0.505. The gains came at a share volume of 571,510 compared to a share volume of 48,040. The market cap stands at $12.95 million.